Home JournalsJournal Details
eISSN: 2573-8348 CAS Zone: Medicine (Zone 4) Emerging Zone: Medicine (Zone 4)

Cancer Reports

Abbr. CANCER REP-US
2.5
Latest IF
Recent Articles
Second‐Line Therapy Following Osimertinib in Metastatic EGFR ‐Mutated Non‐Small‐Cell Lung Cancer at an Academic Medical Center
Rafizadeh M, Bogdan S, Lee J et al · Vol 9(9)
2026-09-23
Comprehensive Profiling of ac4C RNA Modification Identifies CERCAM in Cancer‐Associated Fibroblasts as a Key Prognostic and Microenvironmental Regulator in Colorectal Cancer
Xia Y, Dai J, Zhou X et al · Vol 9(9)
2026-09-23
Sarcopenia and Survival in Patients With Head and Neck Squamous Cell Carcinoma Receiving Immune Checkpoint Inhibitors: A Systematic Review and Meta‐Analysis of Prognostic Association
Koirala D, Malla N, Mishra B et al · Vol 9(9)
2026-09-21
Diffuse‐Type Tenosynovial Giant Cell Tumor of the Hip With Acetabular Bone Involvement: A Case Report With Radiologic‐Pathologic Correlation
Quanbing W, Huanhuan X, Xing Z et al · Vol 9(9)
2026-09-19
Prognostic Factor Analysis for Risk‐Stratified Papillary Thyroid Carcinoma and Nomogram Development for Predicting Structural Incomplete Response to Radioactive Iodine Therapy in Intermediate‐Risk Patients
Li Y, He Z, Zhao M et al · Vol 9(9)
2026-09-16
Survival Outcomes With Cadonilimab Versus PD ‐(L)1 Therapy in Front‐Line Gastric Cancer: A Network Meta‐Analysis
Yu Z, Yi J, Xue J et al · Vol 9(9)
2026-09-16
Prospective Phase II Trial of Biweekly Gemcitabine Plus Nab‐Paclitaxel as First‐Line Therapy in Patients Aged 75 Years and Older With Unresectable Pancreatic Cancer
Ikezawa K, Imai T, Takada R et al · Vol 9(9)
2026-09-15
Comprehensive In Silico Analysis Identifies MSTO1 and LIG1 as Candidate Biomarkers With Diagnostic and Prognostic Relevance in Hepatocellular Carcinoma
Hamad J, Fayyad‐Kazan H, Abdel‐Sater F · Vol 9(9)
2026-09-14
Fewer Injections and Lower Drug Costs With Long‐Acting GnRH Depot Formulations: A Nationwide Analysis of 2.3 Million Patient‐Years in Japan
Kawahara T, Hashizume A, Yamazaki M et al · Vol 9(9)
2026-09-12
Laryngeal NUT Carcinoma With BRD4 :: NUTM1 Fusion: A 4‐Year Clinical Course Highlighting the Limitations of Current Multimodal Therapy
Kanno M, Sasaki C, Kato E et al · Vol 9(9)
2026-09-09
Bufalin Inhibits Melanoma Progression and Endothelial Angiogenic Phenotypes via AKT Signaling
Zhao X, Li M, Qu J · Vol 9(9)
2026-09-08
A POLE P286R ‐Mutated Hepatoid Adenocarcinoma of the Lung Showing Substantial Response to Immune Checkpoint Inhibition
Chernev A, Kaurtseva A, Abasov R et al · Vol 9(9)
2026-09-08
Multi‐Omics Integration Identifies a Five‐Gene Metabolic Signature With Experimental Validation in Clear Cell Renal Cell Carcinoma
Peng Y, Qin S, Li X et al · Vol 9(9)
2026-09-07
First‐Line PD ‐1 Inhibitor‐Based Therapy for Advanced or Metastatic Esophageal Squamous Cell Carcinoma: A Revised Systematic Review and Meta‐Analysis of Phase III Trials
Rothweiler V, Roderburg C, Koeksal M et al · Vol 9(9)
2026-09-07
Endogenous Bornavirus‐Like Nucleoprotein 1 Regulates Cellular Processes and DNA Double‐Strand Breaks in U‐87 MG Glioblastoma Cells
Liang J, Zeng D, Guo Y et al · Vol 9(9)
2026-09-04
A Novel BRCA1 Pathogenic Variant in Tunisian Patient With High Grade Ovarian Cancer: Favorable Therapeutic Response to Olaparib
Ammous‐Boukhris N, Abdelmaksoud‐Dammak R, Feki A et al · Vol 9(9)
2026-09-04
Association Between Temporal Muscle Thickness and Survival in Older Patients With Brain Metastases Undergoing Radiation Therapy
Pikkarainen L, Korhonen T, Tolonen A et al · Vol 9(9)
2026-09-02
AZD6738 (Ceralasertib) Enhances Trifluridine's Antitumor Effect in 5‐ FU –Resistant Colorectal Cancer Cells
Uehara S, Suzuki T, Kato J et al · Vol 9(9)
2026-09-02
Age‐Associated Four‐Gene Prognostic Signature in Breast Cancer
Uchida S · Vol 9(9)
2026-09-02
An In Vitro and In Vivo Assessment of the Anti‐Breast Cancer Activity of Erythrina excelsa Baker (Fabaceae) Bark Extracts
Walantini J, Sipping M, Ymele M et al · Vol 9(9)
2026-09-01
Journal Info
Abbr.
CANCER REP-US
CAS Zone
Medicine (Zone 4) · Non-Top
Emerging Zone
Medicine (Zone 4) · Non-Top
Sub-categories
ONCOLOGYZone 4
Emerging Categories
ONCOLOGYZone 4
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2